Evidence map›Paper›PMID 35434660›Full record

ArticleSTAR protocols2022

A protocol for identifying the binding sites of small molecules on the cystic fibrosis transmembrane conductance regulator (CFTR) protein.

Onofrio Laselva, Evgeniy V Petrotchenko, C Michael Hamilton, Zafar Qureshi, Christoph H Borchers, Robert N Young, Christine E Bear

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in STAR protocols, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 3 countries.

Onofrio LaselvaDepartment of Medical and Surgical Sciences, University of Foggia, Foggia, Italy.
Evgeniy V PetrotchenkoSegal Cancer Proteomics Center, Lady Davis Institute, Jewish General Hospital, McGill University, Montreal, QC, Canada.
C Michael HamiltonDepartment of Chemistry, Simon Fraser University, 8888 University Dr., Burnaby, BC V5A 1S6, Canada.
Zafar QureshiDepartment of Chemistry, Simon Fraser University, 8888 University Dr., Burnaby, BC V5A 1S6, Canada.
Christoph H BorchersSegal Cancer Proteomics Center, Lady Davis Institute, Jewish General Hospital, McGill University, Montreal, QC, Canada.
Robert N YoungDepartment of Chemistry, Simon Fraser University, 8888 University Dr., Burnaby, BC V5A 1S6, Canada.
Christine E BearProgramme in Molecular Medicine, Hospital for Sick Children, 686 Bay Street, Toronto, ON M5G 0A4, Canada.
Simon Fraser University · CAHospital for Sick Children · CAMcGill University · CASkolkovo Institute of Science and Technology · RUUniversity of Foggia · IT

Funding

CIHR
6 · The paper itself

Abstract

We describe a protocol to identify the binding site(s) for a drug called ivacaftor that potentiates the CFTR chloride channel. We use photoaffinity probes-based on the structure of ivacaftor-to covalently modify the CFTR protein at the region that constitutes the drug binding site(s). We define the methods for photo-labeling CFTR, its membrane extraction, and enzymatic digestion using trypsin. We then describe the experimental methods to identify the modified peptides by using mass spectrometry. For complete details on the use and execution of this protocol, please refer to Laselva et al. (2021).

Indexed as

Cystic FibrosisCystic Fibrosis Transmembrane Conductance RegulatorBinding SitesHumansIon TransportMutationCFTR protein, humanCystic Fibrosis Transmembrane Conductance RegulatorCell-based AssaysCell BiologyCell MembraneMass SpectrometryMolecular/Chemical ProbesProtein Biochemistry

Identifiers

PMID35434660
PMCPMC9006651
OpenAlexW4224235561

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.